Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gleevec in KIT-mutated Metastatic Melanoma
NCT00881049Phase 2Completed
- Sponsor
- Peking University
- Start
- Dec 2008
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of imatinib in melanoma, sponsored by Peking University. Primary endpoint: Progression-Free Survival at 12 months. Started Dec 2008; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00881049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00881049.